282 related articles for article (PubMed ID: 36226060)
21. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.
Lu T; Huang Y; Cai Z; Lin W; Chen X; Chen R; Hu Y
Front Pharmacol; 2023; 14():1171302. PubMed ID: 37564176
[No Abstract] [Full Text] [Related]
23. Cemiplimab combined with chemotherapy
Zhu G; Cai H; Zheng Z
Ther Adv Med Oncol; 2023; 15():17588359231213619. PubMed ID: 38028144
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States.
Tian W; Niu L; Wang Z; Lu R; Xiao G; Deng F; Tanzhu G; Zhou R
Front Immunol; 2023; 14():1268070. PubMed ID: 37822936
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting.
Chu RW; Vegas García A; Hickey C; Power DG; Gorry C
Value Health; 2023 Mar; 26(3):402-410. PubMed ID: 36368626
[TBL] [Abstract][Full Text] [Related]
28. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Li Y; Liang X; Li H; Yang T; Guo S; Chen X
Front Pharmacol; 2022; 13():906956. PubMed ID: 35928269
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
31. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Hu X; Hay JW
Lung Cancer; 2018 Sep; 123():166-171. PubMed ID: 30089590
[TBL] [Abstract][Full Text] [Related]
32. Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.
Liu K; Zhu Y; Zhou Y; Zhu H
Adv Ther; 2023 Apr; 40(4):1838-1849. PubMed ID: 36870042
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
35. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
Barbier MC; Pardo E; Panje CM; Gautschi O; Lupatsch JE;
Eur J Health Econ; 2021 Jul; 22(5):669-677. PubMed ID: 33745093
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Liao W; Huang J; Hutton D; Li Q
J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
